nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—Etoposide—muscle cancer	0.132	0.261	CbGbCtD
Irbesartan—CYP1A2—Dacarbazine—muscle cancer	0.121	0.238	CbGbCtD
Irbesartan—CYP2C8—Etoposide—muscle cancer	0.0762	0.15	CbGbCtD
Irbesartan—CYP1A2—Etoposide—muscle cancer	0.059	0.116	CbGbCtD
Irbesartan—CYP3A4—Vincristine—muscle cancer	0.0337	0.0666	CbGbCtD
Irbesartan—CYP2D6—Doxorubicin—muscle cancer	0.0331	0.0654	CbGbCtD
Irbesartan—CYP3A4—Etoposide—muscle cancer	0.0309	0.061	CbGbCtD
Irbesartan—CYP3A4—Doxorubicin—muscle cancer	0.0211	0.0416	CbGbCtD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.00478	0.0344	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TFE3—muscle cancer	0.00473	0.0341	CbGpPWpGaD
Irbesartan—JUN—embryo—muscle cancer	0.00445	0.0672	CbGeAlD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—muscle cancer	0.00416	0.0299	CbGpPWpGaD
Irbesartan—JUN—ATM Signaling Pathway—TP73—muscle cancer	0.00406	0.0292	CbGpPWpGaD
Irbesartan—JUN—Regulation of retinoblastoma protein—PAX3—muscle cancer	0.00403	0.029	CbGpPWpGaD
Irbesartan—JUN—smooth muscle tissue—muscle cancer	0.0035	0.0528	CbGeAlD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.00342	0.0246	CbGpPWpGaD
Irbesartan—JUN—renal system—muscle cancer	0.00337	0.0508	CbGeAlD
Irbesartan—EDNRA—cardiac atrium—muscle cancer	0.00331	0.0499	CbGeAlD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.00308	0.0222	CbGpPWpGaD
Irbesartan—JUN—cardiac atrium—muscle cancer	0.00302	0.0455	CbGeAlD
Irbesartan—EDNRA—tendon—muscle cancer	0.00288	0.0435	CbGeAlD
Irbesartan—EDNRA—vagina—muscle cancer	0.00267	0.0404	CbGeAlD
Irbesartan—AGTR1—smooth muscle tissue—muscle cancer	0.00264	0.0398	CbGeAlD
Irbesartan—JUN—tendon—muscle cancer	0.00263	0.0397	CbGeAlD
Irbesartan—JUN—bone marrow—muscle cancer	0.00255	0.0384	CbGeAlD
Irbesartan—AGTR1—renal system—muscle cancer	0.00254	0.0383	CbGeAlD
Irbesartan—UGT1A3—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.00246	0.0177	CbGpPWpGaD
Irbesartan—JUN—vagina—muscle cancer	0.00244	0.0368	CbGeAlD
Irbesartan—EDNRA—testis—muscle cancer	0.00239	0.036	CbGeAlD
Irbesartan—JUN—BDNF signaling pathway—KIDINS220—muscle cancer	0.00239	0.0172	CbGpPWpGaD
Irbesartan—AGTR1—cardiac atrium—muscle cancer	0.00227	0.0343	CbGeAlD
Irbesartan—JUN—head—muscle cancer	0.00225	0.034	CbGeAlD
Irbesartan—JUN—Apoptosis—TP73—muscle cancer	0.00224	0.0162	CbGpPWpGaD
Irbesartan—JUN—Regulation of retinoblastoma protein—MYOD1—muscle cancer	0.00222	0.016	CbGpPWpGaD
Irbesartan—JUN—testis—muscle cancer	0.00218	0.0329	CbGeAlD
Irbesartan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.00206	0.0149	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—WT1—muscle cancer	0.00201	0.0145	CbGpPWpGaD
Irbesartan—JUN—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—muscle cancer	0.002	0.0144	CbGpPWpGaD
Irbesartan—AGTR1—tendon—muscle cancer	0.00198	0.0299	CbGeAlD
Irbesartan—EDNRA—GPCRs, Other—CNR1—muscle cancer	0.00195	0.0141	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TP63—muscle cancer	0.00193	0.0139	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	0.00188	0.0136	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FOXO1—muscle cancer	0.00186	0.0134	CbGpPWpGaD
Irbesartan—AGTR1—vagina—muscle cancer	0.00184	0.0277	CbGeAlD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP73—muscle cancer	0.00182	0.0131	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	0.00174	0.0125	CbGpPWpGaD
Irbesartan—AGTR1—head—muscle cancer	0.0017	0.0256	CbGeAlD
Irbesartan—AGTR1—testis—muscle cancer	0.00164	0.0247	CbGeAlD
Irbesartan—JUN—Direct p53 effectors—PMS2—muscle cancer	0.0016	0.0115	CbGpPWpGaD
Irbesartan—JUN—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.00158	0.0114	CbGpPWpGaD
Irbesartan—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—muscle cancer	0.00155	0.0112	CbGpPWpGaD
Irbesartan—JUN—Myometrial Relaxation and Contraction Pathways—CALD1—muscle cancer	0.00154	0.0111	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—FOXO4—muscle cancer	0.00151	0.0109	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—TP73—muscle cancer	0.00149	0.0107	CbGpPWpGaD
Irbesartan—JUN—IL6-mediated signaling events—FOXO1—muscle cancer	0.00146	0.0105	CbGpPWpGaD
Irbesartan—CYP2C8—renal system—muscle cancer	0.00138	0.0208	CbGeAlD
Irbesartan—JUN—SIDS Susceptibility Pathways—TP73—muscle cancer	0.00137	0.00985	CbGpPWpGaD
Irbesartan—JUN—Copper homeostasis—FOXO1—muscle cancer	0.00135	0.0097	CbGpPWpGaD
Irbesartan—JUN—Regulation of Androgen receptor activity—FOXO1—muscle cancer	0.00133	0.00956	CbGpPWpGaD
Irbesartan—JUN—ErbB Signaling Pathway—FOXO1—muscle cancer	0.00131	0.00941	CbGpPWpGaD
Irbesartan—CYP1A2—renal system—muscle cancer	0.00129	0.0194	CbGeAlD
Irbesartan—JUN—Direct p53 effectors—TP63—muscle cancer	0.00128	0.00923	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	0.00128	0.00922	CbGpPWpGaD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—PTGS2—muscle cancer	0.00124	0.00896	CbGpPWpGaD
Irbesartan—PTGS1—Overview of nanoparticle effects—PTGS2—muscle cancer	0.00122	0.00877	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.00116	0.00835	CbGpPWpGaD
Irbesartan—PTGS1—smooth muscle tissue—muscle cancer	0.00116	0.0175	CbGeAlD
Irbesartan—PTGS1—renal system—muscle cancer	0.00112	0.0168	CbGeAlD
Irbesartan—JUN—AGE/RAGE pathway—FOXO1—muscle cancer	0.00111	0.00802	CbGpPWpGaD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—muscle cancer	0.00109	0.00788	CbGpPWpGaD
Irbesartan—JUN—Signaling mediated by p38-alpha and p38-beta—PTGS2—muscle cancer	0.00107	0.0077	CbGpPWpGaD
Irbesartan—PTGS1—Eicosanoid Synthesis—PTGS2—muscle cancer	0.00101	0.00727	CbGpPWpGaD
Irbesartan—PTGS1—cardiac atrium—muscle cancer	0.000999	0.0151	CbGeAlD
Irbesartan—JUN—Apoptosis—IGF2—muscle cancer	0.000998	0.00718	CbGpPWpGaD
Irbesartan—JUN—ATM Signaling Pathway—MDM2—muscle cancer	0.000998	0.00718	CbGpPWpGaD
Irbesartan—CYP2C8—vagina—muscle cancer	0.000996	0.015	CbGeAlD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	0.000945	0.00681	CbGpPWpGaD
Irbesartan—CYP3A4—renal system—muscle cancer	0.000932	0.0141	CbGeAlD
Irbesartan—CYP2D6—renal system—muscle cancer	0.000917	0.0138	CbGeAlD
Irbesartan—CYP2C8—testis—muscle cancer	0.000889	0.0134	CbGeAlD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000881	0.00635	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—FOXO1—muscle cancer	0.000877	0.00631	CbGpPWpGaD
Irbesartan—PTGS1—tendon—muscle cancer	0.000871	0.0131	CbGeAlD
Irbesartan—EDNRA—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000848	0.00611	CbGpPWpGaD
Irbesartan—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—muscle cancer	0.000845	0.00608	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.000818	0.00589	CbGpPWpGaD
Irbesartan—JUN—Copper homeostasis—MDM2—muscle cancer	0.000809	0.00582	CbGpPWpGaD
Irbesartan—PTGS1—vagina—muscle cancer	0.000808	0.0122	CbGeAlD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—muscle cancer	0.000805	0.00579	CbGpPWpGaD
Irbesartan—JUN—Regulation of Androgen receptor activity—MDM2—muscle cancer	0.000797	0.00573	CbGpPWpGaD
Irbesartan—CYP2D6—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000796	0.00573	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—CNR1—muscle cancer	0.000793	0.00571	CbGpPWpGaD
Irbesartan—JUN—ErbB Signaling Pathway—MDM2—muscle cancer	0.000785	0.00565	CbGpPWpGaD
Irbesartan—PTGS1—head—muscle cancer	0.000746	0.0113	CbGeAlD
Irbesartan—JUN—Pre-NOTCH Transcription and Translation—TP53—muscle cancer	0.00074	0.00533	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.000735	0.00529	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—HMGA1—muscle cancer	0.000734	0.00528	CbGpPWpGaD
Irbesartan—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000729	0.00525	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000727	0.00523	CbGpPWpGaD
Irbesartan—PTGS1—testis—muscle cancer	0.000721	0.0109	CbGeAlD
Irbesartan—JUN—Regulation of retinoblastoma protein—CDKN2A—muscle cancer	0.000689	0.00496	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000685	0.00493	CbGpPWpGaD
Irbesartan—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	0.000674	0.00485	CbGpPWpGaD
Irbesartan—JUN—Regulation of retinoblastoma protein—MDM2—muscle cancer	0.000668	0.00481	CbGpPWpGaD
Irbesartan—Menopausal symptoms—Doxorubicin—muscle cancer	0.000667	0.00231	CcSEcCtD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000666	0.00479	CbGpPWpGaD
Irbesartan—Renal impairment—Doxorubicin—muscle cancer	0.000661	0.00229	CcSEcCtD
Irbesartan—Paraesthesia—Vincristine—muscle cancer	0.000661	0.00229	CcSEcCtD
Irbesartan—Malaise—Etoposide—muscle cancer	0.000659	0.00228	CcSEcCtD
Irbesartan—JUN—AP-1 transcription factor network—CDKN2A—muscle cancer	0.000657	0.00473	CbGpPWpGaD
Irbesartan—Breast disorder—Methotrexate—muscle cancer	0.000657	0.00228	CcSEcCtD
Irbesartan—Vertigo—Etoposide—muscle cancer	0.000657	0.00228	CcSEcCtD
Irbesartan—EDNRA—GPCR ligand binding—PTCH1—muscle cancer	0.000656	0.00472	CbGpPWpGaD
Irbesartan—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000654	0.00227	CcSEcCtD
Irbesartan—Leukopenia—Etoposide—muscle cancer	0.000654	0.00227	CcSEcCtD
Irbesartan—Abdominal pain—Dactinomycin—muscle cancer	0.000651	0.00226	CcSEcCtD
Irbesartan—Body temperature increased—Dactinomycin—muscle cancer	0.000651	0.00226	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000644	0.00464	CbGpPWpGaD
Irbesartan—Loss of consciousness—Etoposide—muscle cancer	0.000642	0.00223	CcSEcCtD
Irbesartan—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000642	0.00223	CcSEcCtD
Irbesartan—Decreased appetite—Vincristine—muscle cancer	0.00064	0.00222	CcSEcCtD
Irbesartan—Cough—Etoposide—muscle cancer	0.000638	0.00221	CcSEcCtD
Irbesartan—JUN—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000637	0.00459	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Vincristine—muscle cancer	0.000636	0.0022	CcSEcCtD
Irbesartan—Fatigue—Vincristine—muscle cancer	0.000635	0.0022	CcSEcCtD
Irbesartan—Hyponatraemia—Doxorubicin—muscle cancer	0.000632	0.00219	CcSEcCtD
Irbesartan—Hypertension—Etoposide—muscle cancer	0.000631	0.00219	CcSEcCtD
Irbesartan—Constipation—Vincristine—muscle cancer	0.00063	0.00218	CcSEcCtD
Irbesartan—Pain—Vincristine—muscle cancer	0.00063	0.00218	CcSEcCtD
Irbesartan—Asthma—Methotrexate—muscle cancer	0.000628	0.00218	CcSEcCtD
Irbesartan—Chest pain—Etoposide—muscle cancer	0.000622	0.00216	CcSEcCtD
Irbesartan—Affect lability—Doxorubicin—muscle cancer	0.000619	0.00215	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000618	0.00214	CcSEcCtD
Irbesartan—Pancreatitis—Methotrexate—muscle cancer	0.000616	0.00213	CcSEcCtD
Irbesartan—Discomfort—Etoposide—muscle cancer	0.000615	0.00213	CcSEcCtD
Irbesartan—CYP2D6—head—muscle cancer	0.000613	0.00926	CbGeAlD
Irbesartan—Face oedema—Doxorubicin—muscle cancer	0.000608	0.00211	CcSEcCtD
Irbesartan—Hypersensitivity—Dactinomycin—muscle cancer	0.000607	0.0021	CcSEcCtD
Irbesartan—Gastrointestinal pain—Vincristine—muscle cancer	0.000602	0.00209	CcSEcCtD
Irbesartan—Anaphylactic shock—Etoposide—muscle cancer	0.000596	0.00207	CcSEcCtD
Irbesartan—Mood swings—Doxorubicin—muscle cancer	0.000596	0.00207	CcSEcCtD
Irbesartan—CYP2D6—testis—muscle cancer	0.000593	0.00894	CbGeAlD
Irbesartan—Infection—Etoposide—muscle cancer	0.000592	0.00205	CcSEcCtD
Irbesartan—Asthenia—Dactinomycin—muscle cancer	0.000591	0.00205	CcSEcCtD
Irbesartan—JUN—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	0.000591	0.00425	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—VEGFA—muscle cancer	0.000588	0.00424	CbGpPWpGaD
Irbesartan—Neutropenia—Methotrexate—muscle cancer	0.000587	0.00204	CcSEcCtD
Irbesartan—Thrombocytopenia—Etoposide—muscle cancer	0.000584	0.00202	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000584	0.00202	CcSEcCtD
Irbesartan—Tachycardia—Etoposide—muscle cancer	0.000582	0.00202	CcSEcCtD
Irbesartan—Abdominal pain—Vincristine—muscle cancer	0.000582	0.00202	CcSEcCtD
Irbesartan—Body temperature increased—Vincristine—muscle cancer	0.000582	0.00202	CcSEcCtD
Irbesartan—Liver function test abnormal—Doxorubicin—muscle cancer	0.000581	0.00201	CcSEcCtD
Irbesartan—Skin disorder—Etoposide—muscle cancer	0.000579	0.00201	CcSEcCtD
Irbesartan—Hyperhidrosis—Etoposide—muscle cancer	0.000577	0.002	CcSEcCtD
Irbesartan—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000575	0.00199	CcSEcCtD
Irbesartan—Abdominal pain upper—Doxorubicin—muscle cancer	0.000575	0.00199	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000574	0.00414	CbGpPWpGaD
Irbesartan—Photosensitivity reaction—Methotrexate—muscle cancer	0.000573	0.00199	CcSEcCtD
Irbesartan—Hypokalaemia—Doxorubicin—muscle cancer	0.000573	0.00199	CcSEcCtD
Irbesartan—JUN—ATM Signaling Pathway—TP53—muscle cancer	0.000572	0.00412	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00057	0.00411	CbGpPWpGaD
Irbesartan—Breast disorder—Doxorubicin—muscle cancer	0.000569	0.00197	CcSEcCtD
Irbesartan—Anorexia—Etoposide—muscle cancer	0.000568	0.00197	CcSEcCtD
Irbesartan—JUN—Apoptosis—CDKN2A—muscle cancer	0.000568	0.00409	CbGpPWpGaD
Irbesartan—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000567	0.00196	CcSEcCtD
Irbesartan—Diarrhoea—Dactinomycin—muscle cancer	0.000564	0.00195	CcSEcCtD
Irbesartan—Pneumonia—Methotrexate—muscle cancer	0.000563	0.00195	CcSEcCtD
Irbesartan—Nasopharyngitis—Doxorubicin—muscle cancer	0.000563	0.00195	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—MDM2—muscle cancer	0.000562	0.00404	CbGpPWpGaD
Irbesartan—PTGS1—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000562	0.00404	CbGpPWpGaD
Irbesartan—Hypotension—Etoposide—muscle cancer	0.000557	0.00193	CcSEcCtD
Irbesartan—Muscular weakness—Doxorubicin—muscle cancer	0.000555	0.00192	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—HMGA1—muscle cancer	0.000555	0.00399	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—CNR1—muscle cancer	0.000553	0.00398	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—MDM2—muscle cancer	0.000551	0.00397	CbGpPWpGaD
Irbesartan—Renal failure—Methotrexate—muscle cancer	0.000551	0.00191	CcSEcCtD
Irbesartan—JUN—Insulin Signaling—FOXO1—muscle cancer	0.000548	0.00395	CbGpPWpGaD
Irbesartan—Abdominal distension—Doxorubicin—muscle cancer	0.000548	0.0019	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—muscle cancer	0.000544	0.00189	CcSEcCtD
Irbesartan—Asthma—Doxorubicin—muscle cancer	0.000544	0.00189	CcSEcCtD
Irbesartan—Dysphagia—Doxorubicin—muscle cancer	0.000544	0.00189	CcSEcCtD
Irbesartan—Influenza—Doxorubicin—muscle cancer	0.000544	0.00189	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000543	0.00391	CbGpPWpGaD
Irbesartan—Hypersensitivity—Vincristine—muscle cancer	0.000542	0.00188	CcSEcCtD
Irbesartan—Paraesthesia—Etoposide—muscle cancer	0.000536	0.00186	CcSEcCtD
Irbesartan—Pancreatitis—Doxorubicin—muscle cancer	0.000533	0.00185	CcSEcCtD
Irbesartan—JUN—Apoptosis Modulation and Signaling—CDKN2A—muscle cancer	0.000533	0.00384	CbGpPWpGaD
Irbesartan—Dyspnoea—Etoposide—muscle cancer	0.000532	0.00184	CcSEcCtD
Irbesartan—Somnolence—Etoposide—muscle cancer	0.00053	0.00184	CcSEcCtD
Irbesartan—Angina pectoris—Doxorubicin—muscle cancer	0.00053	0.00184	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—muscle cancer	0.00053	0.00184	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—muscle cancer	0.000528	0.00183	CcSEcCtD
Irbesartan—Asthenia—Vincristine—muscle cancer	0.000528	0.00183	CcSEcCtD
Irbesartan—JUN—Androgen receptor signaling pathway—MDM2—muscle cancer	0.000526	0.00379	CbGpPWpGaD
Irbesartan—Vomiting—Dactinomycin—muscle cancer	0.000524	0.00182	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—muscle cancer	0.000523	0.00181	CcSEcCtD
Irbesartan—JUN—Pre-NOTCH Expression and Processing—TP53—muscle cancer	0.000521	0.00375	CbGpPWpGaD
Irbesartan—Rash—Dactinomycin—muscle cancer	0.00052	0.0018	CcSEcCtD
Irbesartan—Decreased appetite—Etoposide—muscle cancer	0.000518	0.0018	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Etoposide—muscle cancer	0.000515	0.00178	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—PTCH1—muscle cancer	0.000515	0.0037	CbGpPWpGaD
Irbesartan—Fatigue—Etoposide—muscle cancer	0.000514	0.00178	CcSEcCtD
Irbesartan—Pain—Etoposide—muscle cancer	0.00051	0.00177	CcSEcCtD
Irbesartan—Constipation—Etoposide—muscle cancer	0.00051	0.00177	CcSEcCtD
Irbesartan—Neutropenia—Doxorubicin—muscle cancer	0.000509	0.00176	CcSEcCtD
Irbesartan—JUN—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	0.000507	0.00365	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000506	0.00364	CbGpPWpGaD
Irbesartan—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000506	0.00175	CcSEcCtD
Irbesartan—EDNRA—Signaling Pathways—KIDINS220—muscle cancer	0.000505	0.00364	CbGpPWpGaD
Irbesartan—Diarrhoea—Vincristine—muscle cancer	0.000504	0.00175	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—muscle cancer	0.000503	0.00174	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—muscle cancer	0.000499	0.00173	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—muscle cancer	0.000497	0.00172	CcSEcCtD
Irbesartan—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000496	0.00172	CcSEcCtD
Irbesartan—Weight increased—Doxorubicin—muscle cancer	0.000495	0.00172	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—muscle cancer	0.000493	0.00171	CcSEcCtD
Irbesartan—Feeling abnormal—Etoposide—muscle cancer	0.000491	0.0017	CcSEcCtD
Irbesartan—Hyperglycaemia—Doxorubicin—muscle cancer	0.000491	0.0017	CcSEcCtD
Irbesartan—Nausea—Dactinomycin—muscle cancer	0.000489	0.0017	CcSEcCtD
Irbesartan—Pneumonia—Doxorubicin—muscle cancer	0.000488	0.00169	CcSEcCtD
Irbesartan—Gastrointestinal pain—Etoposide—muscle cancer	0.000488	0.00169	CcSEcCtD
Irbesartan—Dizziness—Vincristine—muscle cancer	0.000487	0.00169	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—muscle cancer	0.000485	0.00168	CcSEcCtD
Irbesartan—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000481	0.00346	CbGpPWpGaD
Irbesartan—Renal failure—Doxorubicin—muscle cancer	0.000477	0.00165	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000475	0.00342	CbGpPWpGaD
Irbesartan—JUN—Senescence-Associated Secretory Phenotype (SASP)—CDKN2A—muscle cancer	0.000475	0.00342	CbGpPWpGaD
Irbesartan—Urticaria—Etoposide—muscle cancer	0.000474	0.00164	CcSEcCtD
Irbesartan—Jaundice—Doxorubicin—muscle cancer	0.000473	0.00164	CcSEcCtD
Irbesartan—Body temperature increased—Etoposide—muscle cancer	0.000471	0.00163	CcSEcCtD
Irbesartan—Abdominal pain—Etoposide—muscle cancer	0.000471	0.00163	CcSEcCtD
Irbesartan—Conjunctivitis—Doxorubicin—muscle cancer	0.000471	0.00163	CcSEcCtD
Irbesartan—Urinary tract infection—Doxorubicin—muscle cancer	0.000471	0.00163	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—muscle cancer	0.000469	0.00163	CcSEcCtD
Irbesartan—Vomiting—Vincristine—muscle cancer	0.000468	0.00162	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—muscle cancer	0.000467	0.00162	CcSEcCtD
Irbesartan—Rash—Vincristine—muscle cancer	0.000464	0.00161	CcSEcCtD
Irbesartan—JUN—Copper homeostasis—TP53—muscle cancer	0.000464	0.00334	CbGpPWpGaD
Irbesartan—Dermatitis—Vincristine—muscle cancer	0.000464	0.00161	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—CDKN2A—muscle cancer	0.000461	0.00332	CbGpPWpGaD
Irbesartan—Headache—Vincristine—muscle cancer	0.000461	0.0016	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000461	0.00332	CbGpPWpGaD
Irbesartan—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000459	0.00159	CcSEcCtD
Irbesartan—Epistaxis—Doxorubicin—muscle cancer	0.000457	0.00159	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—muscle cancer	0.000456	0.00158	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—muscle cancer	0.000454	0.00157	CcSEcCtD
Irbesartan—Mediastinal disorder—Methotrexate—muscle cancer	0.000453	0.00157	CcSEcCtD
Irbesartan—Agranulocytosis—Doxorubicin—muscle cancer	0.000453	0.00157	CcSEcCtD
Irbesartan—Chills—Methotrexate—muscle cancer	0.000451	0.00156	CcSEcCtD
Irbesartan—JUN—ErbB Signaling Pathway—TP53—muscle cancer	0.00045	0.00324	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—MDM2—muscle cancer	0.000447	0.00322	CbGpPWpGaD
Irbesartan—Bradycardia—Doxorubicin—muscle cancer	0.000443	0.00154	CcSEcCtD
Irbesartan—Hypersensitivity—Etoposide—muscle cancer	0.000439	0.00152	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—muscle cancer	0.000438	0.00152	CcSEcCtD
Irbesartan—Erythema—Methotrexate—muscle cancer	0.000438	0.00152	CcSEcCtD
Irbesartan—Nausea—Vincristine—muscle cancer	0.000437	0.00152	CcSEcCtD
Irbesartan—Rhinitis—Doxorubicin—muscle cancer	0.000436	0.00151	CcSEcCtD
Irbesartan—Hepatitis—Doxorubicin—muscle cancer	0.000435	0.00151	CcSEcCtD
Irbesartan—AGTR1—GPCR ligand binding—CNR1—muscle cancer	0.000434	0.00313	CbGpPWpGaD
Irbesartan—Hypoaesthesia—Doxorubicin—muscle cancer	0.000433	0.0015	CcSEcCtD
Irbesartan—Pharyngitis—Doxorubicin—muscle cancer	0.000432	0.0015	CcSEcCtD
Irbesartan—Urinary tract disorder—Doxorubicin—muscle cancer	0.00043	0.00149	CcSEcCtD
Irbesartan—JUN—Oxidative Stress Induced Senescence—CDKN2A—muscle cancer	0.00043	0.0031	CbGpPWpGaD
Irbesartan—Oedema peripheral—Doxorubicin—muscle cancer	0.000429	0.00149	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—muscle cancer	0.000429	0.00149	CcSEcCtD
Irbesartan—Asthenia—Etoposide—muscle cancer	0.000428	0.00148	CcSEcCtD
Irbesartan—Connective tissue disorder—Doxorubicin—muscle cancer	0.000428	0.00148	CcSEcCtD
Irbesartan—Urethral disorder—Doxorubicin—muscle cancer	0.000427	0.00148	CcSEcCtD
Irbesartan—Pruritus—Etoposide—muscle cancer	0.000422	0.00146	CcSEcCtD
Irbesartan—Visual impairment—Doxorubicin—muscle cancer	0.00042	0.00145	CcSEcCtD
Irbesartan—JUN—Oxidative Stress Induced Senescence—MDM2—muscle cancer	0.000417	0.003	CbGpPWpGaD
Irbesartan—Vision blurred—Methotrexate—muscle cancer	0.000413	0.00143	CcSEcCtD
Irbesartan—Diarrhoea—Etoposide—muscle cancer	0.000408	0.00141	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—muscle cancer	0.000406	0.00141	CcSEcCtD
Irbesartan—Tinnitus—Doxorubicin—muscle cancer	0.000406	0.00141	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—muscle cancer	0.000405	0.0014	CcSEcCtD
Irbesartan—Flushing—Doxorubicin—muscle cancer	0.000404	0.0014	CcSEcCtD
Irbesartan—Cardiac disorder—Doxorubicin—muscle cancer	0.000404	0.0014	CcSEcCtD
Irbesartan—AGTR1—Signaling Pathways—KIDINS220—muscle cancer	0.000396	0.00285	CbGpPWpGaD
Irbesartan—Angiopathy—Doxorubicin—muscle cancer	0.000395	0.00137	CcSEcCtD
Irbesartan—Malaise—Methotrexate—muscle cancer	0.000395	0.00137	CcSEcCtD
Irbesartan—Dizziness—Etoposide—muscle cancer	0.000394	0.00137	CcSEcCtD
Irbesartan—Immune system disorder—Doxorubicin—muscle cancer	0.000393	0.00136	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—muscle cancer	0.000393	0.00136	CcSEcCtD
Irbesartan—Mediastinal disorder—Doxorubicin—muscle cancer	0.000392	0.00136	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—muscle cancer	0.000392	0.00136	CcSEcCtD
Irbesartan—Chills—Doxorubicin—muscle cancer	0.000391	0.00135	CcSEcCtD
Irbesartan—Arrhythmia—Doxorubicin—muscle cancer	0.000389	0.00135	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000385	0.00277	CbGpPWpGaD
Irbesartan—Cough—Methotrexate—muscle cancer	0.000382	0.00132	CcSEcCtD
Irbesartan—Vomiting—Etoposide—muscle cancer	0.000379	0.00131	CcSEcCtD
Irbesartan—Erythema—Doxorubicin—muscle cancer	0.000379	0.00131	CcSEcCtD
Irbesartan—Malnutrition—Doxorubicin—muscle cancer	0.000379	0.00131	CcSEcCtD
Irbesartan—Rash—Etoposide—muscle cancer	0.000376	0.0013	CcSEcCtD
Irbesartan—Dermatitis—Etoposide—muscle cancer	0.000376	0.0013	CcSEcCtD
Irbesartan—Headache—Etoposide—muscle cancer	0.000374	0.0013	CcSEcCtD
Irbesartan—Flatulence—Doxorubicin—muscle cancer	0.000373	0.00129	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—muscle cancer	0.000373	0.00129	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—muscle cancer	0.000373	0.00129	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—muscle cancer	0.000373	0.00129	CcSEcCtD
Irbesartan—Tension—Doxorubicin—muscle cancer	0.000372	0.00129	CcSEcCtD
Irbesartan—Dysgeusia—Doxorubicin—muscle cancer	0.000371	0.00129	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00037	0.00128	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—muscle cancer	0.000368	0.00128	CcSEcCtD
Irbesartan—Nervousness—Doxorubicin—muscle cancer	0.000368	0.00128	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—MDM2—muscle cancer	0.000366	0.00264	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—TP53—muscle cancer	0.000366	0.00263	CbGpPWpGaD
Irbesartan—Muscle spasms—Doxorubicin—muscle cancer	0.000364	0.00126	CcSEcCtD
Irbesartan—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000363	0.00261	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—PTGS2—muscle cancer	0.000357	0.00257	CbGpPWpGaD
Irbesartan—Anaphylactic shock—Methotrexate—muscle cancer	0.000357	0.00124	CcSEcCtD
Irbesartan—Vision blurred—Doxorubicin—muscle cancer	0.000357	0.00124	CcSEcCtD
Irbesartan—Infection—Methotrexate—muscle cancer	0.000355	0.00123	CcSEcCtD
Irbesartan—Nausea—Etoposide—muscle cancer	0.000354	0.00123	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—FH—muscle cancer	0.000354	0.00255	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Doxorubicin—muscle cancer	0.000352	0.00122	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—muscle cancer	0.00035	0.00121	CcSEcCtD
Irbesartan—Anaemia—Doxorubicin—muscle cancer	0.00035	0.00121	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—muscle cancer	0.00035	0.00121	CcSEcCtD
Irbesartan—Agitation—Doxorubicin—muscle cancer	0.000348	0.00121	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—muscle cancer	0.000347	0.0012	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—muscle cancer	0.000345	0.0012	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000345	0.00248	CbGpPWpGaD
Irbesartan—Malaise—Doxorubicin—muscle cancer	0.000342	0.00118	CcSEcCtD
Irbesartan—Vertigo—Doxorubicin—muscle cancer	0.000341	0.00118	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—muscle cancer	0.000341	0.00118	CcSEcCtD
Irbesartan—Syncope—Doxorubicin—muscle cancer	0.00034	0.00118	CcSEcCtD
Irbesartan—Leukopenia—Doxorubicin—muscle cancer	0.000339	0.00118	CcSEcCtD
Irbesartan—EDNRA—Signaling by GPCR—PTCH1—muscle cancer	0.000337	0.00242	CbGpPWpGaD
Irbesartan—Hypotension—Methotrexate—muscle cancer	0.000334	0.00116	CcSEcCtD
Irbesartan—Loss of consciousness—Doxorubicin—muscle cancer	0.000333	0.00115	CcSEcCtD
Irbesartan—Cough—Doxorubicin—muscle cancer	0.000331	0.00115	CcSEcCtD
Irbesartan—Hypertension—Doxorubicin—muscle cancer	0.000327	0.00113	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000325	0.00113	CcSEcCtD
Irbesartan—Myalgia—Doxorubicin—muscle cancer	0.000323	0.00112	CcSEcCtD
Irbesartan—Arthralgia—Doxorubicin—muscle cancer	0.000323	0.00112	CcSEcCtD
Irbesartan—Chest pain—Doxorubicin—muscle cancer	0.000323	0.00112	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—TP53—muscle cancer	0.000322	0.00232	CbGpPWpGaD
Irbesartan—Anxiety—Doxorubicin—muscle cancer	0.000322	0.00111	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—muscle cancer	0.000321	0.00111	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00032	0.00111	CcSEcCtD
Irbesartan—Discomfort—Doxorubicin—muscle cancer	0.000319	0.00111	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—muscle cancer	0.000318	0.0011	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—muscle cancer	0.000318	0.0011	CcSEcCtD
Irbesartan—JUN—Apoptosis—TP53—muscle cancer	0.000316	0.00228	CbGpPWpGaD
Irbesartan—Dry mouth—Doxorubicin—muscle cancer	0.000316	0.00109	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—muscle cancer	0.000314	0.00109	CcSEcCtD
Irbesartan—EDNRA—GPCR downstream signaling—CNR1—muscle cancer	0.000313	0.00225	CbGpPWpGaD
Irbesartan—Decreased appetite—Methotrexate—muscle cancer	0.000311	0.00108	CcSEcCtD
Irbesartan—Anaphylactic shock—Doxorubicin—muscle cancer	0.000309	0.00107	CcSEcCtD
Irbesartan—Oedema—Doxorubicin—muscle cancer	0.000309	0.00107	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000308	0.00107	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—muscle cancer	0.000308	0.00107	CcSEcCtD
Irbesartan—Infection—Doxorubicin—muscle cancer	0.000307	0.00107	CcSEcCtD
Irbesartan—Pain—Methotrexate—muscle cancer	0.000305	0.00106	CcSEcCtD
Irbesartan—Shock—Doxorubicin—muscle cancer	0.000304	0.00105	CcSEcCtD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000304	0.00219	CbGpPWpGaD
Irbesartan—Nervous system disorder—Doxorubicin—muscle cancer	0.000303	0.00105	CcSEcCtD
Irbesartan—Thrombocytopenia—Doxorubicin—muscle cancer	0.000303	0.00105	CcSEcCtD
Irbesartan—Tachycardia—Doxorubicin—muscle cancer	0.000302	0.00105	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—CDKN2A—muscle cancer	0.000301	0.00217	CbGpPWpGaD
Irbesartan—Skin disorder—Doxorubicin—muscle cancer	0.0003	0.00104	CcSEcCtD
Irbesartan—Hyperhidrosis—Doxorubicin—muscle cancer	0.000299	0.00104	CcSEcCtD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TP53—muscle cancer	0.000297	0.00214	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIDINS220—muscle cancer	0.000296	0.00213	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000295	0.00213	CbGpPWpGaD
Irbesartan—Anorexia—Doxorubicin—muscle cancer	0.000295	0.00102	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—muscle cancer	0.000294	0.00102	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—muscle cancer	0.000292	0.00101	CcSEcCtD
Irbesartan—JUN—Cellular Senescence—MDM2—muscle cancer	0.000292	0.0021	CbGpPWpGaD
Irbesartan—Hypotension—Doxorubicin—muscle cancer	0.000289	0.001	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000286	0.00206	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CNR1—muscle cancer	0.000284	0.00204	CbGpPWpGaD
Irbesartan—Urticaria—Methotrexate—muscle cancer	0.000284	0.000984	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—muscle cancer	0.000282	0.000979	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—muscle cancer	0.000282	0.000979	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000282	0.000977	CcSEcCtD
Irbesartan—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	0.00028	0.00201	CbGpPWpGaD
Irbesartan—Paraesthesia—Doxorubicin—muscle cancer	0.000278	0.000963	CcSEcCtD
Irbesartan—Dyspnoea—Doxorubicin—muscle cancer	0.000276	0.000956	CcSEcCtD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000275	0.00198	CbGpPWpGaD
Irbesartan—Somnolence—Doxorubicin—muscle cancer	0.000275	0.000953	CcSEcCtD
Irbesartan—Dyspepsia—Doxorubicin—muscle cancer	0.000272	0.000944	CcSEcCtD
Irbesartan—JUN—Wnt Signaling Pathway and Pluripotency—TP53—muscle cancer	0.000271	0.00195	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.00027	0.00194	CbGpPWpGaD
Irbesartan—Decreased appetite—Doxorubicin—muscle cancer	0.000269	0.000932	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000267	0.000926	CcSEcCtD
Irbesartan—Fatigue—Doxorubicin—muscle cancer	0.000267	0.000924	CcSEcCtD
Irbesartan—JUN—Innate Immune System—FOXO4—muscle cancer	0.000266	0.00192	CbGpPWpGaD
Irbesartan—Constipation—Doxorubicin—muscle cancer	0.000265	0.000917	CcSEcCtD
Irbesartan—Pain—Doxorubicin—muscle cancer	0.000265	0.000917	CcSEcCtD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TP53—muscle cancer	0.000264	0.0019	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—PTCH1—muscle cancer	0.000264	0.0019	CbGpPWpGaD
Irbesartan—Hypersensitivity—Methotrexate—muscle cancer	0.000263	0.000912	CcSEcCtD
Irbesartan—JUN—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	0.000262	0.00188	CbGpPWpGaD
Irbesartan—JUN—Signaling by NOTCH—TP53—muscle cancer	0.000257	0.00185	CbGpPWpGaD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	0.000257	0.00185	CbGpPWpGaD
Irbesartan—Asthenia—Methotrexate—muscle cancer	0.000256	0.000888	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000255	0.00184	CbGpPWpGaD
Irbesartan—Feeling abnormal—Doxorubicin—muscle cancer	0.000255	0.000884	CcSEcCtD
Irbesartan—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000253	0.000877	CcSEcCtD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000253	0.00182	CbGpPWpGaD
Irbesartan—Pruritus—Methotrexate—muscle cancer	0.000253	0.000876	CcSEcCtD
Irbesartan—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000252	0.00182	CbGpPWpGaD
Irbesartan—Urticaria—Doxorubicin—muscle cancer	0.000246	0.000852	CcSEcCtD
Irbesartan—AGTR1—GPCR downstream signaling—CNR1—muscle cancer	0.000245	0.00177	CbGpPWpGaD
Irbesartan—Abdominal pain—Doxorubicin—muscle cancer	0.000245	0.000848	CcSEcCtD
Irbesartan—Body temperature increased—Doxorubicin—muscle cancer	0.000245	0.000848	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—muscle cancer	0.000244	0.000847	CcSEcCtD
Irbesartan—JUN—Oxidative Stress Induced Senescence—TP53—muscle cancer	0.000239	0.00172	CbGpPWpGaD
Irbesartan—Dizziness—Methotrexate—muscle cancer	0.000236	0.000819	CcSEcCtD
Irbesartan—JUN—Immune System—CD34—muscle cancer	0.000228	0.00164	CbGpPWpGaD
Irbesartan—Hypersensitivity—Doxorubicin—muscle cancer	0.000228	0.00079	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—CDKN2A—muscle cancer	0.000227	0.00164	CbGpPWpGaD
Irbesartan—Vomiting—Methotrexate—muscle cancer	0.000227	0.000787	CcSEcCtD
Irbesartan—Rash—Methotrexate—muscle cancer	0.000225	0.000781	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—muscle cancer	0.000225	0.00078	CcSEcCtD
Irbesartan—Headache—Methotrexate—muscle cancer	0.000224	0.000776	CcSEcCtD
Irbesartan—AGTR1—Signaling by GPCR—CNR1—muscle cancer	0.000223	0.0016	CbGpPWpGaD
Irbesartan—Asthenia—Doxorubicin—muscle cancer	0.000222	0.000769	CcSEcCtD
Irbesartan—JUN—Cellular responses to stress—MDM2—muscle cancer	0.00022	0.00159	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—TP53—muscle cancer	0.00022	0.00159	CbGpPWpGaD
Irbesartan—Pruritus—Doxorubicin—muscle cancer	0.000219	0.000759	CcSEcCtD
Irbesartan—JUN—Focal Adhesion—VEGFA—muscle cancer	0.000218	0.00157	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000217	0.00156	CbGpPWpGaD
Irbesartan—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	0.000216	0.00155	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000212	0.00153	CbGpPWpGaD
Irbesartan—Nausea—Methotrexate—muscle cancer	0.000212	0.000736	CcSEcCtD
Irbesartan—Diarrhoea—Doxorubicin—muscle cancer	0.000212	0.000734	CcSEcCtD
Irbesartan—JUN—Direct p53 effectors—TP53—muscle cancer	0.00021	0.00151	CbGpPWpGaD
Irbesartan—Dizziness—Doxorubicin—muscle cancer	0.000205	0.000709	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—MED12—muscle cancer	0.0002	0.00144	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—FH—muscle cancer	0.000199	0.00143	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PTCH1—muscle cancer	0.000199	0.00143	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—TP53—muscle cancer	0.000198	0.00142	CbGpPWpGaD
Irbesartan—Vomiting—Doxorubicin—muscle cancer	0.000197	0.000682	CcSEcCtD
Irbesartan—JUN—Innate Immune System—FOXO1—muscle cancer	0.000197	0.00142	CbGpPWpGaD
Irbesartan—Rash—Doxorubicin—muscle cancer	0.000195	0.000676	CcSEcCtD
Irbesartan—Dermatitis—Doxorubicin—muscle cancer	0.000195	0.000675	CcSEcCtD
Irbesartan—Headache—Doxorubicin—muscle cancer	0.000194	0.000672	CcSEcCtD
Irbesartan—Nausea—Doxorubicin—muscle cancer	0.000184	0.000637	CcSEcCtD
Irbesartan—UGT1A3—Metabolism—ENO2—muscle cancer	0.000182	0.00131	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TP53—muscle cancer	0.000182	0.00131	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FOXO4—muscle cancer	0.000171	0.00123	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CNR1—muscle cancer	0.000168	0.00121	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—VEGFA—muscle cancer	0.000167	0.00121	CbGpPWpGaD
Irbesartan—JUN—Cellular Senescence—TP53—muscle cancer	0.000167	0.00121	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000164	0.00118	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000163	0.00118	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—TP53—muscle cancer	0.000157	0.00113	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PTCH1—muscle cancer	0.000156	0.00112	CbGpPWpGaD
Irbesartan—JUN—Immune System—FOXO4—muscle cancer	0.000155	0.00112	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—KIT—muscle cancer	0.00015	0.00108	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF2—muscle cancer	0.000137	0.000988	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FOXO4—muscle cancer	0.000134	0.000966	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000133	0.000957	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CNR1—muscle cancer	0.000132	0.000948	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—FH—muscle cancer	0.000129	0.000926	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—TP53—muscle cancer	0.000126	0.000911	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—FOXO1—muscle cancer	0.000126	0.000909	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—MDM2—muscle cancer	0.000118	0.000849	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PTCH1—muscle cancer	0.000117	0.000839	CbGpPWpGaD
Irbesartan—JUN—Immune System—FOXO1—muscle cancer	0.000114	0.000824	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000114	0.000818	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MED12—muscle cancer	0.000113	0.00081	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF2—muscle cancer	0.000108	0.000775	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—FH—muscle cancer	0.000106	0.000761	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—FH—muscle cancer	0.000105	0.000754	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ENO2—muscle cancer	0.000103	0.000739	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FOXO4—muscle cancer	0.0001	0.000721	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—FOXO1—muscle cancer	9.91e-05	0.000713	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CNR1—muscle cancer	9.84e-05	0.000708	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—KIT—muscle cancer	9.62e-05	0.000693	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—FH—muscle cancer	8.95e-05	0.000644	CbGpPWpGaD
Irbesartan—JUN—Immune System—KIT—muscle cancer	8.72e-05	0.000628	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF2—muscle cancer	8.04e-05	0.000579	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	8.03e-05	0.000578	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MDM2—muscle cancer	7.58e-05	0.000545	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—KIT—muscle cancer	7.55e-05	0.000543	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—FOXO1—muscle cancer	7.4e-05	0.000533	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MED12—muscle cancer	7.27e-05	0.000523	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FH—muscle cancer	6.91e-05	0.000497	CbGpPWpGaD
Irbesartan—JUN—Immune System—MDM2—muscle cancer	6.87e-05	0.000495	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ENO2—muscle cancer	6.63e-05	0.000477	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PTGS2—muscle cancer	6.35e-05	0.000457	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MED12—muscle cancer	5.97e-05	0.00043	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MDM2—muscle cancer	5.94e-05	0.000428	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MED12—muscle cancer	5.92e-05	0.000426	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—muscle cancer	5.75e-05	0.000414	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—KIT—muscle cancer	5.64e-05	0.000406	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ENO2—muscle cancer	5.44e-05	0.000392	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ENO2—muscle cancer	5.4e-05	0.000388	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	5.18e-05	0.000373	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MED12—muscle cancer	5.06e-05	0.000364	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ENO2—muscle cancer	4.61e-05	0.000332	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—muscle cancer	4.51e-05	0.000325	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MDM2—muscle cancer	4.44e-05	0.00032	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TP53—muscle cancer	4.35e-05	0.000313	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.22e-05	0.000304	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MED12—muscle cancer	3.9e-05	0.000281	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.61e-05	0.00026	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—muscle cancer	3.57e-05	0.000257	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ENO2—muscle cancer	3.56e-05	0.000256	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TP53—muscle cancer	3.41e-05	0.000246	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—muscle cancer	3.37e-05	0.000243	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TP53—muscle cancer	2.55e-05	0.000183	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—muscle cancer	2.31e-05	0.000166	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—muscle cancer	1.9e-05	0.000136	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—muscle cancer	1.88e-05	0.000135	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—muscle cancer	1.61e-05	0.000116	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—muscle cancer	1.24e-05	8.92e-05	CbGpPWpGaD
